Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Enrico Papaleo, Carlo Alviggi, Giorgio Lorenzo Colombo, Claudio Pisanelli, Claudio Ripellino, Salvatore Longobardi & Pier Luigi Canonico. (2014) Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women. Therapeutics and Clinical Risk Management 10, pages 479-484.
Read now
Read now
Articles from other publishers (6)
Peter Sydow, Norbert Gmeinwieser, Katrin Pribbernow, Christoph Keck & Inka Wiegratz. (2020) Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study. Reproductive Biology and Endocrinology 18:1.
Crossref
Crossref
M. Rettenbacher, A.N. Andersen, J.A. Garcia-Velasco, M. Sator, P. Barri, S. Lindenberg, K. van der Ven, Y. Khalaf, U. Bentin-Ley, A. Obruca, G. Tews, M. Schenk, T. Strowitzki, N. Narvekar, K. Sator & B. Imthurn. (2015) A multi-centre phase 3 study comparing efficacy and safety of Bemfola® versus Gonal-f® in women undergoing ovarian stimulation for IVF. Reproductive BioMedicine Online 30:5, pages 504-513.
Crossref
Crossref
Klaus Bühler, Olaf GJ Naether & Wilma Bilger. (2014) A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology. Reproductive Biology and Endocrinology 12:1, pages 6.
Crossref
Crossref
Yuval Bdolah & Neri Laufer. 2013. Altchek's Diagnosis and Management of Ovarian Disorders. Altchek's Diagnosis and Management of Ovarian Disorders
199
206
.
Valentina Gatta, Carla Tatone, Rosanna Ciriminna, Marilena Vento, Sara Franchi, Marco d'Aurora, Samantha Sperduti, Vito Cela, Placido Borzì, Roberto Palermo, Liborio Stuppia & Paolo Giovanni Artini. (2013) Gene expression profiles of cumulus cells obtained from women treated with recombinant human luteinizing hormone + recombinant human follicle-stimulating hormone or highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone alone. Fertility and Sterility 99:7, pages 2000-2008.e1.
Crossref
Crossref
Bruno Lunenfeld. (2011) Gonadotropin stimulation: past, present and future. Reproductive Medicine and Biology 11:1, pages 11-25.
Crossref
Crossref